MND-SMART: Interim Analysis Stage 1 - Amantadine - Results
Dec 2024: Stage 1 interim analysis for amantadine has now been completed and it has been decided to continue testing this drug.
Amantadine to continue
The Euan MacDonald Centre's clinical trial, MND-SMART, has announced that the stage 1 interim analysis for amantadine, the 3rd drug being tested in the MND-SMART platform, has been completed. The independent trial committees have decided that MND-SMART should continue to test amantadine in the trial.
All trial participants will continue to take their study drug, so that the team can continue collecting data to determine whether amantadine slows down MND progression.
Adaptive trial
MND-SMART is an adaptive trial, which means that researchers can test drugs that may slow the progression of motor neuron disease (MND), efficiently and definitively. It also means that the trial can stop testing drugs that are unlikely to be effective according to emerging results.
The committees commended the MND-SMART trial sites across all 4 UK nations, on the number of participants involved in the trial and the high rate of data completeness provided.
Our sincere thanks to every person with MND who has contributed, their families, local research delivery teams, funders & collaborators.
Further reading and information
To find out more on the stage 1 interim analysis for amantadine visit the MND-SMART website.
Related content
Register interest in joining the trial (UK only)
Sponsors and funders
Euan MacDonald Centre for Motor Neuron Disease Research, MND Scotland, My Name'5 Doddie Foundation, Alan Davidson Foundation, MND Association, Baillie Gifford